Skip to content

Efficacy of tibolone and raloxifene for the maintenance of skeletal muscle strength, bone mineral density, balance, body composition cognitive function, mood/depression, anxiety and quality of life / well-being in late postmenopausal women > 70 years: Study design of a randomized, double-blind, double-dummy, placebo-controlled, single-center trial

Efficacy of tibolone and raloxifene for the maintenance of skeletal muscle strength, bone mineral density, balance, body composition cognitive function, mood/depression, anxiety and quality of life / well-being in late postmenopausal women ¡Ý 70 years: Study design of a randomized, double-blind, double-dummy, placebo-controlled, single-center trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON23828
Enrollment
324
Registered
2008-01-18
Start date
2003-07-15
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

muscle strenth, BMD, body composition, cognition spierkracht, botmineraaldichtheid, lichaamssamenstelling

Interventions

Muscle power and muscle strength: - Maximum voluntary isometric knee extension strength (both legs) was measured as the force applied at the ankle, with the subject seated in an adjustable straight-b

Sponsors

dr HJJ Verhaar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Healthy postmenopausal women 2. Minimum age 70 years at the time of inclusion 3. Body mass index between 18 and 35 kg/m2 4. Subjects should be willing and able to comply with the protocol for the duration of the study, after written informed consent

Exclusion criteria

Exclusion criteria: 1. Steroid therapy or other drugs affecting muscle mass taken during the last 6 months 2. History or presence of any malignancy (except non-melanoma skin cancers) 3. Undiagnosed abnormal vaginal bleeding in the past year prior to screening 4. Presence or history of endometrial hyperplasia with or without atypia 5. Presence or history of cardiovascular, cerebrovascular or thrombo-embolic disorders 6. Current liver or renal disease or history of this condition 7. Uncontrolled hypertension (systolic blood pressure > 170 mm Hg systolic and/or diastolic blood pressure >105 mm Hg) 8. Osteoporosis: Z-score < -2 9. Bone disease other than osteoporosis such as Paget's disease 10. Osteomalacia or bone metastases 11. Alcohol abuse (average intake of more than 4 alcohol containing units per day) 12. Smoking more than 10 cigarettes/day 13. Use of sex hormones, corticosteroids, insulin, anti-coagulants or enzyme-inducing drugs 14. Treatment with tibolone or raloxifene within the last 6 months 15. Known hypersensitivity to tibolone or raloxifene 16. Presence of any condition, concomitant disease, intercurrent illness or resultant therapy that would interfere either with the participants's compliance or with the results of the study and/or their evaluation 17. Major problems with locomotion and cognitive impairment (MMSE <24) 18. Participation in another study.

Design outcomes

Primary

MeasureTime frame
Primary endpoints are muscle strength and bone mineral density.

Secondary

MeasureTime frame
The secondary endpoints are postural balance, body composition, cognitive function, anxiety, mood and quality of life.

Contacts

Public ContactD.E. Jacobsen

Postbus 85500

D.Jacobsen@umcutrecht.nl088-7558280

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)